Dana-Farber Cancer Institute

Articles

Study Suggests Lymphoma Patients With Depression or Anxiety Experience Shorter Survival Times

June 9th 2023

Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma had shorter survival times than patients without a mental health diagnosis.

Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting

May 30th 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers.

Dana-Farber Researchers Report on the Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer

May 22nd 2023

People living with HIV remain at higher risk than people living without HIV for developing various cancers that can be treated with immune checkpoint inhibitors.

Three-drug Combination Slows Progression of Advanced Kidney Cancer

May 16th 2023

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

International Study Shows Many Younger Women with Breast Cancer Can Safely Have a Baby

May 9th 2023

A new study published today in the New England Journal of Medicine found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur.

Combination Therapy a Promising Option for Advanced Kidney Cancer Patients Already Treated With Immunotherapy

April 28th 2023

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute’s Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, a VEGF TKI, plus belzutifan, a HIF-2α inhibitor.

Research Uncovers Alternate Mechanism for Producing Key Protein in Metastatic Prostate Cancer

April 17th 2023

In a new study in the journal Nature Cancer, Dana-Farber Cancer Institute scientists shed new light on the mechanism that raises and lowers PSMA expression in prostate cancer cells.

Sox9 Protein Enables Molecular Time Travel That Can Lead to Colorectal Cancer

April 5th 2023

Research from Dana-Farber Cancer Institute looks at what happens before the emergence of mutations that interrupt cellular differentiation in colorectal cancer and finds not only evidence of fetal reprogramming that can initiate cancer, but also a protein, Sox9, that fuels that reprogramming.

Novobiocin Attacks BRCA-Mutated Cancer Cells from Within and Without, Study Shows

March 31st 2023

As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells.

Dana-Farber Researchers Chart a Course for Understanding, Preventing, and Treating Young-onset Colorectal Cancer

March 29th 2023

Dana-Farber Cancer Institute researchers outline the complexities of colorectal cancer and the research needed to map out a path toward understanding it.

Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer

February 16th 2023

Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration for the treatment of metastatic HR+, HER2- breast cancer.

Results of the SORAYA Study Show Conjugate Therapy Produced Remissions in One-third of Patients With Drug-Resistant Ovarian Cancer

February 10th 2023

In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments.

Three-Drug Combination Therapy Effective in Patients with High-Risk CLL, Trial Shows

February 1st 2023

A three-drug combination that sent chronic lymphocytic leukemia into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

Study Finds That Risk of Adverse Effects From Cancer Immunotherapy is Higher in Patients With Certain Inherited Genetic Variations

January 30th 2023

In a new study, scientists at Dana-Farber Cancer Institute identify, for the first time, inherited genetic variations that place patients at high risk for these complications.

CAR-T-cell Shows Promise in Patients With Lymphoma of the Brain and Spinal Cord in Early Trial

January 24th 2023

A CAR-T-cell therapy known as axicabtagene ciloleucel is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord.

Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/Oncologists

December 22nd 2022

As patients with cancer increasingly receive treatment in community hospitals and clinics and many such centers experience a shortage of oncologists, a group of physicians at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School has proposed the first-ever training blueprint for oncologists planning careers in a community or academic-community setting.

Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter Syndrome

December 21st 2022

In a new study, scientists reveal for the first time the genomic differences between chronic lymphocytic leukemia and Richter's, the molecular pathways by which Richter's emerges, and the existence of multiple subtypes of the disease.

New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer

December 14th 2022

A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which clonal hematopoiesis patients are at highest risk for cancer progression.

Dana-Farber Researchers to Present Findings at San Antonio Breast Cancer Symposium

December 6th 2022

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 44th annual San Antonio Breast Cancer Symposium on December 7-10th.

Study Shows That Immune System Holds Clues To Patients With High-risk Smoldering Myeloma Likely To Benefit From Treatment

December 1st 2022

In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes in immune system cells can indicate which patients with high-risk "smoldering" myeloma are likely to progress to myeloma and which will benefit the most from treatment.